Antonella Napolitano

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi request reprint Validation of a quantitative magnetic resonance method for measuring human body composition
    Antonella Napolitano
    Clinical Unit Cambridge, GlaxoSmithKline Clinical Pharmacology and Discovery Medicine, Addenbrooke s Hospital, Cambridge, UK
    Obesity (Silver Spring) 16:191-8. 2008
  2. ncbi request reprint Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498
    Pradeep J Nathan
    GlaxoSmithKline, Clinical Unit Cambridge, Addenbrooke s Hospital, Hills Road, Cambridge CB2 2GG UK
    J Clin Pharmacol 52:1456-67. 2012
  3. ncbi request reprint Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals
    Samuel R Chamberlain
    Clinical Unit Cambridge, GlaxoSmithKline, Addenbrooke s Hospital, Cambridge CB0 0QQ, UK
    Psychopharmacology (Berl) 224:501-9. 2012
  4. ncbi request reprint The relationship between fat mass, eating behaviour and obesity-related psychological traits in overweight and obese individuals
    Barry V O'Neill
    Experimental Medicine, GlaxoSmithKline R and D, Clinical Unit Cambridge, UK
    Appetite 59:656-61. 2012
  5. ncbi request reprint Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and alprazolam following insulin-induced hypoglycemia in humans
    Ameera X Patel
    Brain Mapping Unit, Behavioral and Clinical Neuroscience Institute, University of Cambridge, Cambridge, CB2 3EB, UK
    Psychopharmacology (Berl) 231:3817-28. 2014
  6. ncbi request reprint Quantitative magnetic resonance (QMR) for longitudinal evaluation of body composition changes with two dietary regimens
    Khin Swe Myint
    Institute of Metabolic Science, Metabolic Research Laboratories, Cambridge, UK
    Obesity (Silver Spring) 18:391-6. 2010
  7. ncbi request reprint The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans
    Boris A Chizh
    Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Cambridge and Harlow, UK
    Pain 132:132-41. 2007
  8. ncbi request reprint Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist
    Pradeep J Nathan
    Clinical Unit Cambridge, Cambridge, UK
    J Clin Pharmacol 52:464-74. 2012
  9. ncbi request reprint Neuropsychiatric adverse effects of centrally acting antiobesity drugs
    Pradeep J Nathan
    Experimental Medicine, GlaxoSmithKline, Clinical Unit Cambridge, UK
    CNS Neurosci Ther 17:490-505. 2011

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Validation of a quantitative magnetic resonance method for measuring human body composition
    Antonella Napolitano
    Clinical Unit Cambridge, GlaxoSmithKline Clinical Pharmacology and Discovery Medicine, Addenbrooke s Hospital, Cambridge, UK
    Obesity (Silver Spring) 16:191-8. 2008
    ..To evaluate a novel quantitative magnetic resonance (QMR) methodology (EchoMRI-AH, Echo Medical Systems) for measurement of whole-body fat and lean mass in humans...
  2. ncbi request reprint Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498
    Pradeep J Nathan
    GlaxoSmithKline, Clinical Unit Cambridge, Addenbrooke s Hospital, Hills Road, Cambridge CB2 2GG UK
    J Clin Pharmacol 52:1456-67. 2012
    ..These findings provide encouraging safety, tolerability, and pharmacokinetic data in support of the continued clinical development of GSK1521498...
  3. ncbi request reprint Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals
    Samuel R Chamberlain
    Clinical Unit Cambridge, GlaxoSmithKline, Addenbrooke s Hospital, Cambridge CB0 0QQ, UK
    Psychopharmacology (Berl) 224:501-9. 2012
    ..Binge-eating represents a useful model of 'behavioural addiction' for exploring this issue...
  4. ncbi request reprint The relationship between fat mass, eating behaviour and obesity-related psychological traits in overweight and obese individuals
    Barry V O'Neill
    Experimental Medicine, GlaxoSmithKline R and D, Clinical Unit Cambridge, UK
    Appetite 59:656-61. 2012
    ....
  5. ncbi request reprint Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and alprazolam following insulin-induced hypoglycemia in humans
    Ameera X Patel
    Brain Mapping Unit, Behavioral and Clinical Neuroscience Institute, University of Cambridge, Cambridge, CB2 3EB, UK
    Psychopharmacology (Berl) 231:3817-28. 2014
    ..Orexin signaling is thus an exciting potential therapeutic target for disorders of sleep, feeding, addiction, and stress...
  6. ncbi request reprint Quantitative magnetic resonance (QMR) for longitudinal evaluation of body composition changes with two dietary regimens
    Khin Swe Myint
    Institute of Metabolic Science, Metabolic Research Laboratories, Cambridge, UK
    Obesity (Silver Spring) 18:391-6. 2010
    ..0 and 0.7 kg lower than those obtained with 4C (P = 0.0008) and DXA (P = 0.049), respectively. Measurement precision remained high. QMR measurement should prove valuable for quantifying modest changes of FM in small trials...
  7. ncbi request reprint The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans
    Boris A Chizh
    Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Cambridge and Harlow, UK
    Pain 132:132-41. 2007
    ..These data provide the first clinical evidence that a TRPV1 antagonist may alleviate pain and hyperalgesia associated with inflammation and tissue injury...
  8. ncbi request reprint Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist
    Pradeep J Nathan
    Clinical Unit Cambridge, Cambridge, UK
    J Clin Pharmacol 52:464-74. 2012
    ..These findings provide encouraging data in support of the development of GSK1521498 for the treatment of disorders of maladaptive ingestive behavior or compulsive consumption...
  9. ncbi request reprint Neuropsychiatric adverse effects of centrally acting antiobesity drugs
    Pradeep J Nathan
    Experimental Medicine, GlaxoSmithKline, Clinical Unit Cambridge, UK
    CNS Neurosci Ther 17:490-505. 2011
    ....